The studies didn’t demonstrate a causal relationship between semaglutide—the ingredient used in both Ozempic and Wegovy—and the condition, the Danish drugmaker said.The company’s internal safety assessment and evaluation of the research studies determined that the benefit-risk profile of semaglutide remains unchanged,

The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes drug Ozempic to a rare eye disease.

Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have strengthened the link between Novo Nordisk’s blockbuster GLP-1 and a rare eye disease.

Denmark's drug regulator has asked the European Medicine Agency's safety committee to evaluate two studies that found a potential link between Novo Nordisk's (NVO) type 2 diabetes drug Ozempic (semaglutide) and a rare eye condition.